Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Sodium Carbonate | HCID 10340 | — |
| Reactant | 4-(3-Chloropropyl)morpholine | HCID 95834 | — |
| Reactant | HCID 136016305 | HCID 136016305 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 57642345 | HCID 57642345 | 69.8% |
Reaction Steps
A mixture of 1.8281 g (0.005 mole) of 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-8-hydroxy-2H-1,4-benzodiazepin-2-one (Ipp) from the previous step, 0.636 g of sodium carbonate, 0.9818 g (0.006 mole) of 4-(3-chloropropyl)-morpholine and 50 mL of dimethylformamide was stirred at 50° C., under an argon atmosphere for 73 hours. The mixture was then cooled and partitioned between ethyl acetate and saturated sodium bicarbonate. The aqueous layer was then reextracted with ethyl acetate. The ethyl acetate layers were washed successively with saturated sodium bicarbonate, water, brine and then dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-8-(3-(4-morpholinyl)propoxy)-2H-1,4-benzodiazepin-2-one (Ij). Pure 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-8-(3-(4-morpholinyl)propoxy)-2H-1,4-benzodiazepin-2-one (Ij) (1.721 g) was obtained by silica gel chromatography eluting with ethyl acetate-methanol (90:10). MH+/Z=492.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07524840B2 |
|---|
| Source dataset | uspto-grants-2009_04 |
|---|
| ORD ID | ord-a561fee74061458cb64e3e400c18ee15 |
|---|
| Source note | uspto-grants-2009_04 |
|---|